Every 10-Q that Moleculin Biotech, Inc. (MBRX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow MBRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MBRX filings page.
Moleculin Biotech is a clinical‑stage oncology company focused on Annamycin (naxtarubicin), a "next‑generation" anthracycline. It is running the pivotal Phase 2/3 MIRACLE trial in relapsed/refractory AML, where preliminary unblinded Part A data for 45 patients showed complete remission (CR) rates of 43% and 36% in the two Annamycin arms versus 12% for the control, and CRc rates of 50% and 57% versus 29%. Pooled data from five trials (n=90) showed no evidence of drug‑related cardiotoxicity despite high cumulative doses.
For the six months ended June 30, 2026, the company reported no revenue and a net loss of $20.5 million, with R&D of $10.8 million driven largely by MIRACLE. Cash and cash equivalents were $7.3 million against an accumulated deficit of $226.5 million, and management disclosed substantial doubt about its ability to continue as a going concern. Subsequent to quarter‑end, an August 2026 equity/warrant offering raised $9.3 million gross, which, together with existing cash, is expected to fund operations into the first quarter of 2027, but the company estimates it needs roughly $8 million more to support MIRACLE and operations into the second quarter of 2027.
Moleculin Biotech’s quarterly report shows a clinical-stage company investing heavily in its lead cancer drug while facing meaningful funding pressure. For the quarter ended March 31, 2026, it reported no revenue and a net loss of $12.8 million, wider than $5.9 million a year earlier, driven largely by higher research and development spending of $5.4 million as the pivotal Phase 2B/3 MIRACLE trial for Annamycin advances.
Cash and cash equivalents were $10.3 million with total assets of $23.4 million, and management states this cash is not sufficient to fund operations for at least one year, raising substantial doubt about the company’s ability to continue as a going concern. A February 2026 warrant inducement brought in gross proceeds of about $8.3 million and created new Series H warrants, while at-the-market share sales added smaller amounts of capital.
The company believes its cash plus approximately $0.8 million raised after quarter-end will fund operations into the third quarter of 2026 and estimates it needs roughly $25 million of additional financing to support the MIRACLE trial and operations into the first quarter of 2027. Operationally, Moleculin progressed MIRACLE enrollment, highlighted blinded efficacy rates it views as favorable versus historical cytarabine data, closed its Australian subsidiary to cut overhead, and extended Annamycin patent protection in Hong Kong through 2040.
Moleculin Biotech reported a wider quarterly loss and a new stockholders’ deficit. For Q3 2025, net loss was $25,399,000 as operating expenses fell to $5,906,000 but were overshadowed by a $20,609,000 loss on issuance of warrant liabilities. Year‑to‑date net loss reached $49,112,000.
Cash and cash equivalents were $6,703,000 as of September 30, 2025, up from $4,278,000 at year‑end, aided by warrant exercises and equity transactions. Total assets were $20,353,000. A new long‑term warrant liability of $41,333,000 and accumulated losses drove stockholders’ equity to a deficit of $26,920,000.
The company disclosed substantial doubt about its ability to continue as a going concern, noting current cash is not sufficient for at least one year. It received Nasdaq notices related to stockholders’ equity and bid price, with an extension to November 19, 2025 for equity compliance and a bid‑price compliance period until December 24, 2025. In 2025, Moleculin completed multiple financings, including a June offering with Series E warrants ($0.37 exercise price) and an August inducement generating $6.0 million and issuing Series F warrants ($0.55 exercise price). A July 2025 ATM program authorizes up to $6.5 million.
Moleculin Biotech, Inc. (MBRX) is a clinical-stage pharmaceutical company advancing its lead drug Annamycin in a global Phase 3 pivotal trial (MIRACLE). As of June 30, 2025, the company reported $7.6 million in cash, $21.6 million in total assets, $28.8 million in total liabilities and an accumulated deficit of $167.4 million. Net loss was $7.64 million for Q2 2025 and $14.08 million for the six months ended June 30, 2025. The company recorded a $20.55 million warrant liability and recognized a $10.4 million loss on issuance related to its June 2025 offering.
The MIRACLE Phase 3 program is active in 35+ sites across the US, EU and Eastern Europe with 8 subjects treated as of July 25, 2025 and planned interim unblinding by end of 2025. Regulators: EMA approved CTAs for nine EU countries; FDA provided positive pediatric study feedback. Nasdaq notified the company of deficiencies on equity and bid-price listing standards; a plan to regain compliance was submitted on July 3, 2025. Management disclosed substantial doubt about going concern and is seeking additional financing.